MS Patients Have Significant And Sustained Reduction In Disability And Risk Of Relapse On Alemtuzumab Versus Approved Therapy, Rebif(R)
アレムツズマブ、CD52、MS、Bayer
2008年10月28日火曜日
Centocor, Inc. Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis - News, Search Jobs, Events
2008年10月26日日曜日
NEJM -- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
CAMPATHがMSに、IFNbetaよりも効くそうです。
でも、免疫応答を下げることの副作用も、出てしまう。
甲状腺炎の割合がCAMPATHのほうでかなり高いですが、MSのほうが重篤だろうので、トレードオフが許容されるのかな。
NEJM -- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
Alemtuzumab significantly reduced the rate of sustained accumulation of disability, as compared with interferon beta-1a (9.0% vs. 26.2%; hazard ratio, 0.29; 95% confidence interval [CI], 0.16 to 0.54; P<0.001) color="#ff0000">0.10 vs. 0.36; hazard ratio, 0.26; 95% CI, 0.16 to 0.41; P<0.001). p="0.005)." p="0.02)." color="#ff0000">23% vs. 3%] and immune thrombocytopenic purpura [3% vs. 1%]) and infections (66% vs. 47%). There were no significant differences in outcomes between the 12-mg dose and the 24-mg dose of alemtuzumab.
でも、免疫応答を下げることの副作用も、出てしまう。
甲状腺炎の割合がCAMPATHのほうでかなり高いですが、MSのほうが重篤だろうので、トレードオフが許容されるのかな。
NEJM -- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
Alemtuzumab significantly reduced the rate of sustained accumulation of disability, as compared with interferon beta-1a (9.0% vs. 26.2%; hazard ratio, 0.29; 95% confidence interval [CI], 0.16 to 0.54; P<0.001) color="#ff0000">0.10 vs. 0.36; hazard ratio, 0.26; 95% CI, 0.16 to 0.41; P<0.001). p="0.005)." p="0.02)." color="#ff0000">23% vs. 3%] and immune thrombocytopenic purpura [3% vs. 1%]) and infections (66% vs. 47%). There were no significant differences in outcomes between the 12-mg dose and the 24-mg dose of alemtuzumab.
[癌ワクチン]TroVax
Oxford BioMedica社
癌ワクチン・TroVax
効いているんだろうか？
BioToday - 癌ワクチン・TroVaxに対する免疫応答と生存が関連する
Cancer Vaccine Shows Promise In Patients With Bowel, Kidney And Prostate Cancer
OxfordBiomedica-TroVax
20th EORTC-NCI-AACR
TroVax is made up of a modified virus (Modified Vaccinia Ankara (MVA)), which acts as a vehicle to transport a second component, a gene that produces an antigen that is present in most solid tumours, called 5T4. TroVax is injected into patients whose solid tumours have the 5T4 tumour antigen present, so that the vaccine can trigger the body's natural immune responses to mobilise against 5T4.
ECCO-the European CanCer Organisation (2008, October 26). Cancer Vaccine Shows Promise In Patients With Bowel, Kidney And Prostate Cancer. ScienceDaily. Retrieved October 26, 2008, from http://www.sciencedaily.com /releases/2008/10/081023195220.htm
癌ワクチン・TroVax
効いているんだろうか？
BioToday - 癌ワクチン・TroVaxに対する免疫応答と生存が関連する
Cancer Vaccine Shows Promise In Patients With Bowel, Kidney And Prostate Cancer
OxfordBiomedica-TroVax
20th EORTC-NCI-AACR
TroVax is made up of a modified virus (Modified Vaccinia Ankara (MVA)), which acts as a vehicle to transport a second component, a gene that produces an antigen that is present in most solid tumours, called 5T4. TroVax is injected into patients whose solid tumours have the 5T4 tumour antigen present, so that the vaccine can trigger the body's natural immune responses to mobilise against 5T4.
ECCO-the European CanCer Organisation (2008, October 26). Cancer Vaccine Shows Promise In Patients With Bowel, Kidney And Prostate Cancer. ScienceDaily. Retrieved October 26, 2008, from http://www.sciencedaily.com /releases/2008/10/081023195220.htm
Pfizer rheumatoid arthritis drug effective in study | Industries | Healthcare | Reuters
RAREUTERに抗RAが3題。PfizerのCP690, RocheのaIL6R, J&JのaTNFa(ゴリムマブ)。学会が近い？
CP-690,550
Pfizer rheumatoid arthritis drug effective in study Industries Healthcare ReutersSignificantly more patients reached the ACR 20 goal on the medicine than did those who received a placebo.
tocilizumab
Roche arthritis drug effective in late-stage trial
メトトレキセートとの併用で統計的優位に効果あり。
In the study involving nearly 1,200 patients, those who received Actemra by infusion every four weeks plus an older medicine, methotrexate, experienced significantly lower progression of joint erosion and joint space narrowing than those who received methotrexate and a placebo.
Both the 8 milligram/kilogram and 4 mg/kg doses achieved statistical significance compared to the placebo group, according to data to be presented at the American College of Rheumatology meeting in San Francisco next week.
Actemra, known chemically as tocilizumab, is an anti-interleukin-6 receptor antibody and works in a different way than the existing class of biotechnology medicines that block an inflammatory protein called tumor necrosis factor (TNF), such as Roche and Genentech Inc's (DNA.N: Quote, Profile, Research, Stock Buzz) Rituxan.
golimumab(sc, 4週に1度)
J&J arthritis drug effective after 1 year-study
The drug, a next-generation anti-TNF therapy, is administered every four weeks by subcutaneous injection. Anti-TNF drugs are a class of biotechnology medicines, including J&J's Remicade, that are used to treat inflammatory diseases.
Through one year, 78 percent of patients who continued in the golimumab 50 mg group and 74 percent of patients on the 100 mg dose achieved the ACR 20 goal, researchers said. Some attained ACR 50 and ACR 70 responses, they said.
CP-690,550
Pfizer rheumatoid arthritis drug effective in study Industries Healthcare ReutersSignificantly more patients reached the ACR 20 goal on the medicine than did those who received a placebo.
tocilizumab
Roche arthritis drug effective in late-stage trial
メトトレキセートとの併用で統計的優位に効果あり。
In the study involving nearly 1,200 patients, those who received Actemra by infusion every four weeks plus an older medicine, methotrexate, experienced significantly lower progression of joint erosion and joint space narrowing than those who received methotrexate and a placebo.
Both the 8 milligram/kilogram and 4 mg/kg doses achieved statistical significance compared to the placebo group, according to data to be presented at the American College of Rheumatology meeting in San Francisco next week.
Actemra, known chemically as tocilizumab, is an anti-interleukin-6 receptor antibody and works in a different way than the existing class of biotechnology medicines that block an inflammatory protein called tumor necrosis factor (TNF), such as Roche and Genentech Inc's (DNA.N: Quote, Profile, Research, Stock Buzz) Rituxan.
golimumab(sc, 4週に1度)
J&J arthritis drug effective after 1 year-study
The drug, a next-generation anti-TNF therapy, is administered every four weeks by subcutaneous injection. Anti-TNF drugs are a class of biotechnology medicines, including J&J's Remicade, that are used to treat inflammatory diseases.
Through one year, 78 percent of patients who continued in the golimumab 50 mg group and 74 percent of patients on the 100 mg dose achieved the ACR 20 goal, researchers said. Some attained ACR 50 and ACR 70 responses, they said.
Mini antibodies: biotech's next big thing? | Science | Reuters
MiniAbMini antibodies: biotech's next big thing? Science Reuters: "Mini antibodies: biotech's next big thing?"
まとまってますね。
まとまってますね。
BioToday - Ablynx社 2つの標的に対するNanobodiesの共同開発でMerck KGaA社と合意
BioToday - Ablynx社 2つの標的に対するNanobodiesの共同開発でMerck KGaA社と合意 2008.9
Ablynx.pipeline
パイプラインでは、ALX-0081(anti-vWF), ALX-0681が、2008年末にそれぞれPII, IND申請が終わるとのこと。
ACS(acute coronary syndrome)とTTP(thrombotic thrombocytopenic purpura)適用狙い。
ACSなら、すぐ消失しちゃっても、良いのかな。
In the study, treatment with the Nanobody®did not result in detectable immunogenicity. 抗原性でないんですね、驚き！
References
Ablynx社 Boehringer Ingelheim社とのアルツハイマー病研究提携が延長された 2008.8
Ablynx社がワイス社とNanobody技術による抗体医薬開発で提携
Nanobody.org
抗TNF抗体断片などを結合したNanobodyが動物モデルで効果 2005
Ablynx.com
Ablynx社 Nanobody（ナノボディ）治療の開発でBoehringer Ingelheim社と提携 2007.8
Ablynx.pipeline
パイプラインでは、ALX-0081(anti-vWF), ALX-0681が、2008年末にそれぞれPII, IND申請が終わるとのこと。
ACS(acute coronary syndrome)とTTP(thrombotic thrombocytopenic purpura)適用狙い。
ACSなら、すぐ消失しちゃっても、良いのかな。
In the study, treatment with the Nanobody®did not result in detectable immunogenicity. 抗原性でないんですね、驚き！
References
Ablynx社 Boehringer Ingelheim社とのアルツハイマー病研究提携が延長された 2008.8
Ablynx社がワイス社とNanobody技術による抗体医薬開発で提携
Nanobody.org
抗TNF抗体断片などを結合したNanobodyが動物モデルで効果 2005
Ablynx.com
Ablynx社 Nanobody（ナノボディ）治療の開発でBoehringer Ingelheim社と提携 2007.8
登録:
コメント (Atom)